<a href='https://academicmedicaleducation.com/daniel-kuritzkes-md'>Daniel Kuritzkes, MD</a> Brigham and Women's Hospital; Harvard Medical School, United States Conflict of Interest Disclosure Receipt of grants/research support from Atea, Gilead, Merck, and ViiV Receipt of honoraria or consultation fees from Abpro, Atea, Decoy, Gilead, GlaxoSmithKline, Merck, Novartis, Rigel, ViiV

Daniel Kuritzkes, MD Brigham and Women's Hospital; Harvard Medical School, United States Conflict of Interest Disclosure Receipt of grants/research support from Atea, Gilead, Merck, and ViiV Receipt of honoraria or consultation fees from Abpro, Atea, Decoy, Gilead, GlaxoSmithKline, Merck, Novartis, Rigel, ViiV

<a href="https://academicmedicaleducation.com/daniel-kuritzkes-md" rel="noopener noreferrer">Daniel Kuritzkes, MD</a> Brigham and Women's Hospital; Harvard Medical School, United States Conflict of Interest Disclosure Receipt of grants/research support from Atea, Gilead, Merck, and ViiV Receipt of honoraria or consultation fees from Abpro, Atea, Decoy, Gilead, GlaxoSmithKline, Merck, Novartis, Rigel, ViiV

#2 Daniel Kuritzkes - Monoclonal Antibodies

How will the world look like in 2022? Is SARS-CoV-2 here to stay with us? While some countries are opening towards normal life, albeit with cautious optimism, others are experiencing the hardest disease burden and public health crisis so far. Will vaccines be effective against new variants and how long the protection will last? What do we know so far about long COVID? Which patient populations could benefit most from emerging therapeutic options? Would there be resistance to new therapies? Subscribe to the COVID-19 Science & Society podcast to find out more on the most relevant and timely topics concerning the COVID pandemic.

Medicine

Health & Fitness

How will the world look like in 2022? Is SARS-CoV-2 here to stay with us? While some countries are opening towards normal life, albeit with cautious optimism, others are experiencing the hardest disease burden and public health crisis so far. Will vaccines be effective against new variants and how long the protection will last? What do we know so far about long COVID? Which patient populations could benefit most from emerging therapeutic options? Would there be resistance to new therapies? Subscribe to the COVID-19 Science &amp; Society podcast to find out more on the most relevant and timely topics concerning the COVID pandemic.

Share #2 Daniel Kuritzkes - Monoclonal Antibodies

Sign up to save your podcasts

#2 Daniel Kuritzkes - Monoclonal Antibodies

#2 Daniel Kuritzkes - Monoclonal Antibodies